诺和诺德：Wegovy 减肥药或提振市场情绪，我们看好上行空间；维持 “买入” 评级

Summary of Novo Nordisk (NOVOb.CO) Conference Call Company Overview - Company: Novo Nordisk (NOVOb.CO) - Market Cap: Dkr1.7 trillion / $260.8 billion - Enterprise Value: Dkr1.8 trillion / $281.8 billion - Industry: Pharmaceuticals and Life Sciences - Current Price: Dkr373.85 - 12-Month Price Target: Dkr436.00 (Upside: 16.6%) [1][2] Key Points and Arguments 1. Wegovy Pill Launch - The launch of the Wegovy pill is expected to significantly impact the obesity market, with potential for increased addressable population due to Medicare volume unlock in 2H'26 [1] - Sales estimates for 2027-29 are projected to be 25-35% above company consensus, assuming a market share of approximately 33% [1][15] - The company anticipates that the Wegovy pill will drive positive earnings momentum and sentiment in the near term [1] 2. Market Share and Competitive Landscape - A previous KOL survey suggested a market share closer to 50:50, indicating potential upside risk to consensus estimates for the Wegovy pill [1][15] - The upcoming launch of Lilly's orforglipron in April 2026 is expected to be a key competitor, with the company monitoring prescription data closely [1][32] 3. Financial Performance and Guidance - For FY25, revenue growth is expected at the top end of the company's guidance (8-11% CER growth), driven by higher obesity sales expectations [16] - FY26 guidance is anticipated to be conservative, with revenue growth projected between -6% to 0%, reflecting uncertainties around prescription inflection from Medicare unlock [21][22] - The company is expected to guide for operating profit growth of -6% to 0% CER, with a significant FX impact [21][22] 4. Valuation Adjustments - Target price increased to DKK436 from DKK352 due to the potential positive impact of the Wegovy pill launch [1][16] - DCF analysis suggests a valuation of DKK440 per share, reflecting a revised terminal growth rate assumption [16] 5. Risks and Catalysts - Risks include potential statistical inferiority of CagriSema in upcoming REDEFINE trials, which could lead to a 12% downside risk to shares [1][15] - Key catalysts include the performance of the Wegovy pill and the Medicare volume unlock, which are expected to drive stock performance in 2H'26 [1][15] 6. Debates and Strategic Focus - Key debates for 2026 include the ramp-up of oral Wegovy and capital allocation following the acquisition of Metsera by Pfizer [25][40] - Concerns about cannibalization of the injectable Wegovy by the oral version are noted, but the company believes that overall market growth potential remains strong [26][29] 7. Sales Projections for Oral Wegovy - Projected global sales for oral Wegovy are DKK 4,250 million ($650 million) in 2026, with peak sales expected to reach DKK 40,800 million ($6.2 billion) by 2031 [35] Additional Important Information - The company is focusing on maintaining a strong manufacturing setup to support the production of both oral and injectable medications, which may help mitigate competitive pressures [29][30] - The tolerability profile of oral Wegovy is similar to that of injectable Wegovy, which may enhance its market acceptance [28][31] This summary encapsulates the key insights and projections discussed in the conference call regarding Novo Nordisk's strategic direction, financial outlook, and market positioning within the obesity treatment landscape.